Table 2 Pharmacist recommendations and acceptance rates
DDI pair | CMA reviews (n) | Pharmacists’ recommendations (n (%)) | Acceptance (%) |
|---|---|---|---|
Factor Xa inhibitor + other anticoagulant | 7216 | 80 (1.1) | 100 |
QTc prolonging agent + antiarrhythmic agent (flecainide, sotalol) (QTc) | 2283 | 72 (3.2) | 80.4 |
Antiarrhythmic agent (flecainide, amiodarone, sotalol) + antipsychotic (QTc) | 834 | 38 (4.6) | 78.4 |
Dabigatran + other anticoagulant | 943 | 8 (0.8) | 100 |
Antiarrhythmic agent (flecainide, amiodarone, sotalol) + tricyclic and related antidepressant (QTc) | 631 | 26 (4.1) | 57.1 |
Statin (simvastatin, atorvastatin) + non-azithromycin macrolides | 477 | 60 (12.6) | 63.5 |
Quetiapine + CYP3A4 inhibitor | 319 | 32 (10.0) | 76.0 |
Statin (simvastatin, atorvastatin) + azole antifungal agent | 209 | 17 (8.1) | 71.4 |
Statin (simvastatin, rosuvastatin) + cyclosporine | 199 | 10 (5.0) | 66.7 |
Opioid + MAO inhibitor | 92 | 5 (5.4) | 100 |
CYP3A4 substrate + CYP3A4 inducer | 107 | 19 (17.8) | 73.3 |
Valproic acid + carbapenem | 63 | 10 (15.9) | 80.0 |
Saccharomyces boulardii + glucocorticoid (high dose) | 69 | 2 (2.9) | 0 |
Vitamin K antagonist + acetylsalicylic acid (analgetic dose) | 78 | 2 (2.6) | 100 |
Droperidol, pimozide + macrolide (QTc) | 57 | 0 (0) | NA |
Intravenous calcium + ceftriaxone | 60 | 2 (3.3) | 100 |
Antiarrhythmic agent (flecainide, amiodarone, sotalol, propafenone) + quinolone (QTc) | 56 | 5 (8.9) | 75.0 |
Serotonergic antidepressant + linezolid | 40 | 6 (15.0) | 20.0 |
Colchicine + CYP3A4 inhibitor (strong) | 48 | 3 (6.3) | 100 |
Colchicine + macrolide | 74 | 2 (2.7) | 100 |
Factor Xa inhibitor + azole antifungal agent | 40 | 4 (10.0) | 75.0 |
Live vaccine + glucocorticoid | 26 | 0 (0) | NA |
Alcohol containing drugs + disulfiram | 30 | 0 (0) | NA |